Furthermore, our identification of higher rates of PIK3CA mutations may suggest that understanding the specific pathways that are altered with immunosuppressive agents may lead to new pathway specific immunosuppression that will reduce the increased risk for CRC and other cancers. Here, PIK3CA is linked to cancer.